7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

Recent clinical trials suggest that blockade of integrins is a promising strategy for the treatment of acute coronary syndromes. Administration of 7E3 monoclonal antibody (mAb) Fab fragment (c7E3 Fab) directed against platelet integrin IIb/IIIa (alpha IIb beta 3, CD41/CD61) reduces acute ischemic complications of coronary angioplasty and clinical restenosis at 6 months. However, 7E3 mAb is not selective for platelet IIb/IIIa but also cross-reacts with the leukocyte integrin Mac-1 (alpha M beta 2, CD11b/CD18) and the vitronectin receptor (alpha v beta 3, CD51/CD61). Information regarding how this mAb may affect other cells important in vascular repair is scant. Potential interactions of c7E3 Fab with inflammatory (i.e., monocytes and neutrophils), vascular smooth muscle, and endothelial cells may contribute to the in vivo actions of c7E3 Fab. In this study we explored the binding of 7E3 to monocytic cells and the functional effect of 7E3 and c7E3 Fab on Mac-1-mediated adhesion to fibrinogen (FGN) and intercellular adhesion molecule-1 (ICAM-1), ligands abundant in the injured vessel wall. Flow cytometry demonstrated that 7E3 bound to THP-1 monocytic cells and identified a subpopulation (approximately 10%) of Mac-1 that was qualitatively similar to that recognized by CBRM1/5, a mAb directed to an activation-specific neoepitope present on a subset of Mac-1 molecules. mAb 7E3 bound to K562 cells transfected with just the alpha subunit (CD11b) of Mac-1 but not to nontransfected cells, confirming a direct interaction between 7E3 and Mac-1. mAb 7E3 and c7E3 Fab blocked the adhesion of Mac-1-bearing cells to FGN (80 +/- 11% and 78 +/- 9% inhibition, respectively) and ICAM-1 (62 +/- 14% and 62 +/- 17%). Both 7E3 and c7E3 Fab significantly inhibited (70 +/- 6% and 62 +/- 26%) soluble FGN binding to human peripheral blood monocytes. Thus, c7E3 Fab cross-reacts with the CD11b subunit of Mac-1 and interrupts cell-extracellular matrix and cell-cell adhesive interactions and may thereby influence the recruitment of circulating monocytes to sites of vessel injury. Given the recent evidence that adherent and infiltrating monocyte number directly correlates with the extent of neointimal hyperplasia, inhibition of Mac-1-dependent adhesion and IIb/IIIa-dependent function by c7E3 Fab may jointly contribute to the regulation of vascular repair and to the sustained clinical benefits observed with c7E3 Fab after angioplasty.

[1]  Eric J. Topol,et al.  Textbook of Interventional Cardiology , 1999 .

[2]  E. Edelman,et al.  Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[3]  C. Smith,et al.  Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? , 1995, Journal of the American College of Cardiology.

[4]  W. Wong,et al.  Mechanisms of pertussis toxin‐induced myelomonocytic cell adhesion: role of Mac‐1(CD11b/CD18) and urokinase receptor (CD87) , 1996, Immunology.

[5]  A. Boyd,et al.  A common epitope on platelet integrin alpha IIb beta 3 (glycoprotein IIbIIIa; CD41b/CD61) and alpha M beta 2 (Mac-1; CDIIb/CD18) detected by a monoclonal antibody. , 1996, Journal of Immunology.

[6]  M. Horton.  Adhesion Receptors as Therapeutic Targets , 1995 .

[7]  E. Topol,et al.  Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.

[8]  P. Serruys,et al.  Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. , 1995, Circulation.

[9]  N. Hogg,et al.  Antibodies that activate β2 integrins can generate different ligand binding states , 1995, European journal of immunology.

[10]  S. Rosenberg,et al.  Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.

[11]  D. Altieri,et al.  Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain. , 1994, The Journal of biological chemistry.

[12]  Timothy A. Springer,et al.  The dynamic regulation of integrin adhesiveness , 1994, Current Biology.

[13]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[14]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[15]  J. Loscalzo,et al.  Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. , 1993, Blood.

[16]  P. Libby,et al.  Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury , 1993, Circulation.

[17]  S. Ortlepp,et al.  KIM185, a monoclonal antibody to CD18 which induces a change in the conformation of CD18 and promotes both LFA‐1‐ and CR3‐dependent adhesion , 1993, European journal of immunology.

[18]  D. Waltz,et al.  Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. , 1993, The Journal of clinical investigation.

[19]  M. Diamond,et al.  The I domain is a major recognition site on the leukocyte integrin Mac- 1 (CD11b/CD18) for four distinct adhesion ligands , 1993, The Journal of cell biology.

[20]  M. Diamond,et al.  A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen , 1993, The Journal of cell biology.

[21]  P. Serruys,et al.  Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. , 1993, Journal of the American College of Cardiology.

[22]  C M Gibson,et al.  Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. , 1993, Journal of the American College of Cardiology.

[23]  D Schwartz,et al.  A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression , 1992, Circulation.

[24]  E J Topol,et al.  The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. , 1992, Journal of the American College of Cardiology.

[25]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[26]  E. Butcher,et al.  Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events. , 1992, Journal of immunology.

[27]  B. Rollins,et al.  JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. , 1992, Circulation research.

[28]  F. Sánchez‐Madrid,et al.  Regulated expression and function of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and triggering of proliferation through CD11c/CD18 , 1991, The Journal of experimental medicine.

[29]  D. Altieri,et al.  Occupancy of CD11b/CD18 (Mac-1) divalent ion binding site(s) induces leukocyte adhesion. , 1991, Journal of immunology.

[30]  R. Califf,et al.  Clinical trials of restenosis after coronary angioplasty. , 1991, Circulation.

[31]  Timothy A. Springer,et al.  Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation , 1991, Cell.

[32]  Xiaoping Du,et al.  Ligands “activate” integrin α IIb β 3 (platelet GPIIb-IIIa) , 1991, Cell.

[33]  M. Cybulsky,et al.  Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.

[34]  J. Loike,et al.  CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Altieri,et al.  Signal transduction initiated by extracellular nucleotides regulates the high affinity ligand recognition of the adhesive receptor CD11b/CD18. , 1990, Journal of immunology.

[36]  H. Rosen,et al.  The role of the type 3 complement receptor in the induced recruitment of myelomonocytic cells to inflammatory sites in the mouse. , 1990, American journal of respiratory cell and molecular biology.

[37]  N. Hogg,et al.  Regulated expression of Mg2+ binding epitope on leukocyte integrin alpha subunits. , 1989, The EMBO journal.

[38]  B. Waller.  Pathology of transluminal balloon angioplasty used in the treatment of coronary heart disease. , 1989, Cardiology clinics.

[39]  A. Schmaier,et al.  High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets , 1989, The Journal of cell biology.

[40]  Spencer B. King,et al.  Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia , 1989 .

[41]  R. Juliano,et al.  Phorbol ester modulation of integrin-mediated cell adhesion: a postreceptor event , 1989, The Journal of cell biology.

[42]  K. Resch,et al.  TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. , 1989, European journal of cell biology.

[43]  P. Mannucci,et al.  Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen , 1988, The Journal of cell biology.

[44]  T S Edgington,et al.  A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). , 1988, Journal of immunology.

[45]  D. Altieri,et al.  Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Loike,et al.  Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[47]  E. Chi,et al.  A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits. , 1988, The Journal of clinical investigation.

[48]  P. J. Simpson,et al.  Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. , 1988, The Journal of clinical investigation.

[49]  P W Serruys,et al.  Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. , 1988, Circulation.

[50]  M. Nobuyoshi,et al.  Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.

[51]  H. Rosen,et al.  Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo , 1987, The Journal of experimental medicine.

[52]  Richard O. Hynes,et al.  Integrins: A family of cell surface receptors , 1987, Cell.

[53]  I. Charo,et al.  Platelet glycoproteins IIb and IIIa: evidence for a family of immunologically and structurally related glycoproteins in mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P. Mannucci,et al.  Binding of fibrinogen to human monocytes. , 1986, The Journal of clinical investigation.

[55]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[56]  Gary R. Grotendorst,et al.  Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity , 1986, Nature.

[57]  B. Coller.  A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. , 1985, The Journal of clinical investigation.

[58]  B. Coller,et al.  A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. , 1983, The Journal of clinical investigation.

[59]  R. Ross,et al.  Human monocyte-derived growth factor(s) for mesenchymal cells: Activation of secretion by endotoxin and concanavalin A , 1981, Cell.

[60]  R. Ross,et al.  A macrophage-dependent factor that stimulates the proliferation of fibroblasts in vitro. , 1976, The American journal of pathology.

[61]  A. Böyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[62]  Duff Gl,et al.  The morphology of early atherosclerotic lesions of the aorta demonstrated by the surface technique in rabbits fed cholesterol; together with a description of the anatomy of the intima of the rabbit's aorta and the spontaneous lesions which occur in it. , 1957 .